DBS effectiveness against nonmotor features in PD is similar to those of infusion therapies. Host: Fiona Gupta, USA Yes: Abdelhamid Benazzouz, France No: Keyoumars Ashkan, UK When is the right time to refer PD patients for deep brain stimulation?
Host: Mike Samuel, UK Late: Patricia Limousin, UK Early: Vladimira Vuletic, Croatia Clinical assessment in PD – Motor assessment is the key and nonmotor is not required
Host: Irene Litvan, USA No: Pedro Garcia Ruiz, Spain Should untroubling dyskinesia be treated?
Host: Daniel Kremens, USA Yes: Rajesh Pahwa, USA No: Ray Chaudhuri, UK Should PD patients carrying (GBA) mutations be treated differently from gene negative?
Yes: Anthony Schapira, UK No: Rajesh Pahwa, USA Is continuous dopaminergic stimulation better strategy than pulsatile in every patient?
Host: Fernando Pagan, USA Yes: Stuart Isaacson, USA No: Tatyana Simuni, USA Is CSF alpha-snyuclein a useful biomarker for PD?
Host: Michael Ugrumov, Russia Yes: Georgia Xiromerisiou, Greece No: Mark F. Lew, USA Are there important environmental factors for PD?
Host: Alastair Noyce, UK Yes: Cristian Falup-Pecurariu, Romania No: Zvezdan Pirtosek, Slovenia The personalized Parkinson’s
Ray Chaudhuri, UK Clinical pathological conference (CPC)